However, possibly due to the very low numbers of CSC in these early-stage breast tumors, and the absence of chemotherapy which may have heightened CXCL8- and FASL release, it was not possible to demonstrate a decrease in P-FAK and P-AKT since the baseline value assessed by IHC was 0 in most patients. The gene discussed is PTK2; the disease is breast neoplasm.